<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566485</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 17107</org_study_id>
    <secondary_id>NCI-2018-01159</secondary_id>
    <nct_id>NCT03566485</nct_id>
  </id_info>
  <brief_title>Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer</brief_title>
  <official_title>BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stand Up To Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of idasanutlin when given&#xD;
      together with atezolizumab, and to see how well atezolizumab and cobimetinib or idasanutlin&#xD;
      work in treating participants with stage IV estrogen-receptor positive (ER+) breast cancer,&#xD;
      or ER+ breast cancer that has come back (recurrent) and cannot be removed by surgery&#xD;
      (unresectable). Monoclonal antibodies, such as atezolizumab, may interfere with the ability&#xD;
      of tumor cells to grow and spread. Cobimetinib and idasanutlin may stop the growth of tumor&#xD;
      cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with&#xD;
      cobimetinib or atezolizumab with idasanutlin may work better in treating participants with&#xD;
      estrogen-receptor positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and tolerability of atezolizumab and idasanutlin in patients with&#xD;
      estrogen receptor positive (ER+) metastatic breast cancer (mBC) (Phase I).&#xD;
&#xD;
      II. To determine the anti-tumor effect of atezolizumab and cobimetinib or idasanutlin in&#xD;
      patients with ER+ mBC (Phase II).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the anti-tumor duration of effect of atezolizumab and cobimetinib or&#xD;
      idasanutlin in patients with ER+ mBC (Phase II).&#xD;
&#xD;
      II. To determine the safety and tolerability of atezolizumab and cobimetinib or idasanutlin&#xD;
      in patients with ER+ mBC (Phase II).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate if CD8+ T cells are enhanced in the tumor with either MEK or MDM2 inhibition&#xD;
      (Phase II).&#xD;
&#xD;
      II. To evaluate if MHC-I/II and/or PD-L1 expression is enhanced with MEK inhibition (Phase&#xD;
      II).&#xD;
&#xD;
      III. To evaluate if T cell chemotractants (CCL5, CXCL9,10,11,13) are upregulated upon MDM2&#xD;
      antagonism (Phase II).&#xD;
&#xD;
      IV. To determine if baseline or changes in PDL1 expression, MHC expression, presence of tumor&#xD;
      infiltrating lymphocytes, neoantigen expression/ mutation burden (using ribonucleic acid&#xD;
      [RNA]-and whole exome sequencing), CCL5, CXCL9, CXCL10, CXCL11, and CXCL13 correlate with&#xD;
      clinical outcome (Phase II).&#xD;
&#xD;
      V. To determine if immunological activity of MEK inhibition can be tracked noninvasively&#xD;
      using Zr^89-atezolizumab (Phase II).&#xD;
&#xD;
      OUTLINE: This is a phase 1, dose-escalation study of idasanutlin followed by a phase II&#xD;
      study. Participants are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Participants with TP53 gene mutation receive atezolizumab intravenously (IV) over 60&#xD;
      minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and&#xD;
      cobimetinib orally (PO) daily on days 1-21. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Participants without TP53 gene mutation receive atezolizumab IV over 60 minutes&#xD;
      starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and&#xD;
      idasanutlin PO daily on days 1-5. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual/Loss of funding&#xD;
  </why_stopped>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)</measure>
    <time_frame>At 28 days</time_frame>
    <description>Assessment of DLT for the patients in the atezolizumab and idasanutiln arm of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (Phase I)</measure>
    <time_frame>At 28 days</time_frame>
    <description>Assessment of MTD for the atezolizumab and idasanutiln combination arm of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose (Phase I)</measure>
    <time_frame>At 28 days</time_frame>
    <description>Assessment of recommended phase II dose for the atezolizumab and idasanutiln combination arm of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)</measure>
    <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
    <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) (Phase II)</measure>
    <time_frame>At 6 months</time_frame>
    <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses + stability of disease at 6 months seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Related Response Criteria (irRC) (Phase II)</measure>
    <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
    <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of immune-related complete and partial responses seen in patients with measurable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) (Phase II) in Days</measure>
    <time_frame>At 12 months</time_frame>
    <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and disease progression.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase II) in Days</measure>
    <time_frame>At 12 months</time_frame>
    <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (Phase II)</measure>
    <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
    <description>Assessment of adverse events throughout the phase II study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Stage III Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Estrogen Receptor-positive</condition>
  <condition>HER2/Neu Negative</condition>
  <arm_group>
    <arm_group_label>Phase 2 (atezolizumab, cobimetinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO</arm_group_label>
    <arm_group_label>Phase 2 (atezolizumab, cobimetinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Phase 2 (atezolizumab, cobimetinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idasanutlin</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Signed and dated written informed consent.&#xD;
&#xD;
          -  Subjects ≥ 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence&#xD;
             of invasive mammary carcinoma that is:&#xD;
&#xD;
               -  ER/PR-positive (&gt; 1% cells) by IHC and HER2 negative per ASCO guidelines (by IHC&#xD;
                  or FISH)&#xD;
&#xD;
               -  Previously exposed to an aromatase inhibitor (AI) or a selective&#xD;
                  estrogen-receptor modulator/ downregulator (SERM; SERD) + a CDK4/6 inhibitor&#xD;
&#xD;
               -  Appropriate candidates for chemotherapy&#xD;
&#xD;
               -  Amenable to biopsy at the time of study entry&#xD;
&#xD;
          -  Adequate organ function including:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 × 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9/g/dL (may have been transfused)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤&#xD;
                  2.5 × ULN (or ≤ 5 × ULN if liver metastases are present)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as&#xD;
                  calculated using the Cockcroft-Gault (CG) equation&#xD;
&#xD;
               -  Thyroid Stimulating Hormone (TSH) ≤ 1 x ULN&#xD;
&#xD;
               -  Amylase ≤ 1 x ULN&#xD;
&#xD;
               -  Lipase ≤ 1 x ULN&#xD;
&#xD;
               -  CPK ≤ 1.5 x ULN&#xD;
&#xD;
               -  LVEF (echo) ≥ LLN (Cobi arm only)&#xD;
&#xD;
          -  Female patients of childbearing potential must agree to use at least two methods of&#xD;
             acceptable contraception with a failure rate of &lt; 1% per year from 15 days prior to&#xD;
             first trial treatment administration until at least 5 months after study participant's&#xD;
             final dose of study drugs. See appendix C for details.&#xD;
&#xD;
        Note: Females of childbearing potential are defined as those who are not surgically sterile&#xD;
        or post-menopausal (i.e. patient has not had a bilateral tubal ligation, a bilateral&#xD;
        oophorectomy, or a complete hysterectomy; or has not been amenorrheic for 12 months without&#xD;
        an alternative medical cause). Post-menopausal status in females under 55 years of age&#xD;
        should be confirmed with a serum follicle-stimulating hormone (FSH) level within laboratory&#xD;
        reference range for postmenopausal women.&#xD;
&#xD;
          -  Patients unable to read/write in English are eligible to participate in the overall&#xD;
             study but will not participate in the Patient-Reported Outcome questionnaires&#xD;
             throughout the trial&#xD;
&#xD;
          -  Re-enrollment of a subject that has discontinued the study as a pre-treatment screen&#xD;
             failure (i.e. a consented patient who did not receive study drugs) is permitted. If&#xD;
             re-enrolled, the subject must be re-consented. Only the screening procedures performed&#xD;
             outside of protocol-specified timing must be repeated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with anti-PD-L1 and anti-PD1 antibodies, MEK inhibitors or MDM2&#xD;
             antagonists.&#xD;
&#xD;
          -  No more than 3 lines of chemotherapy in the metastatic setting&#xD;
&#xD;
          -  No concurrent anticancer therapy. Required washout from prior therapy:&#xD;
&#xD;
               -  Endocrine therapy: no required wash-out&#xD;
&#xD;
               -  Chemotherapy: 14 days&#xD;
&#xD;
               -  Major surgery: 14 days (provided wound healing is adequate)&#xD;
&#xD;
               -  Radiation: 7 days&#xD;
&#xD;
               -  Investigational/Biologic Therapy (half -life ≤ 40 hours): 14 days&#xD;
&#xD;
               -  Investigational/Biologic Therapy (half -life &gt; 40 hours): 28 days&#xD;
&#xD;
               -  Use of corticosteroids or immunosuppressive medication is exclusionary, except&#xD;
                  the following in the absence of active autoimmune disease:&#xD;
&#xD;
                    -  Subjects are permitted the use of corticosteroids with minimal systemic&#xD;
                       absorption (e.g. topical, ocular, intra-articular, intranasal, and inhaled);&#xD;
&#xD;
                    -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or&#xD;
                       equivalent are permitted;&#xD;
&#xD;
                    -  Adrenal replacement steroid doses including doses &gt; 10 mg daily prednisone&#xD;
                       are permitted;&#xD;
&#xD;
                    -  A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g.&#xD;
                       CT scan premedication against contrast dye allergy) or for treatment of&#xD;
                       non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction&#xD;
                       caused by a contact allergen) is permitted.&#xD;
&#xD;
          -  Previous malignant disease other than breast cancer within the last 5 years, with the&#xD;
             exception of basal or squamous cell carcinoma of the skin, cervical carcinoma in situ,&#xD;
             or low-risk cancers considered curatively treated (i.e. complete remission achieved at&#xD;
             least 2 years prior to first dose of study drugs AND additional therapy not required&#xD;
             while receiving study treatment).&#xD;
&#xD;
          -  All subjects with brain metastases, except those meeting the following criteria:&#xD;
&#xD;
               -  Brain metastases that have been treated locally and are clinically stable for at&#xD;
                  least 2 weeks prior to enrollment&#xD;
&#xD;
               -  No history of intracranial or spinal cord hemorrhage&#xD;
&#xD;
               -  No evidence of interim CNS disease progression&#xD;
&#xD;
               -  Metastasis to the midbrain, pons, and medulla&#xD;
&#xD;
               -  No ongoing neurological symptoms that are related to the brain localization of&#xD;
                  the disease (sequelae that are a consequence of the treatment of the brain&#xD;
                  metastases are acceptable.&#xD;
&#xD;
               -  Subjects must be either off steroids or on a stable or decreasing dose of ≤ 10 mg&#xD;
                  daily prednisone (or equivalent)&#xD;
&#xD;
          -  Receipt of any organ transplantation including allogeneic stem-cell transplantation.&#xD;
&#xD;
          -  Significant acute or chronic infections including, among others:&#xD;
&#xD;
               -  Known history of testing positive for human immunodeficiency virus (HIV), or&#xD;
                  acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
               -  Active tuberculosis&#xD;
&#xD;
               -  Positive test for hepatitis B virus (HBV) surface antigen (and/or core antibody)&#xD;
                  and/or confirmatory hepatitis C virus (HCV) RNA (if anti-HCV antibody tested&#xD;
                  positive).&#xD;
&#xD;
          -  Active autoimmune disease with reasonable possibility of clinically significant&#xD;
             deterioration when receiving an immunostimulatory agent:&#xD;
&#xD;
               -  Subjects with Type 1 diabetes mellitus, vitiligo, psoriasis, hypo- or&#xD;
                  hyperthyroid disease not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
               -  Subjects requiring hormone replacement with corticosteroids are eligible if the&#xD;
                  steroids are administered only for the purpose of hormonal replacement and at&#xD;
                  doses ≤ 10 mg or 10 mg equivalent prednisone per day.&#xD;
&#xD;
               -  Administration of steroids through a route known to result in a minimal systemic&#xD;
                  exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable.&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or which may interfere with the&#xD;
             detection or management of suspected drug-related pulmonary toxicity.&#xD;
&#xD;
          -  Uncontrolled asthma [defined as having 3 or more of the following features of&#xD;
             partially controlled asthma within 28 days prior to starting study treatment: Daytime&#xD;
             symptoms more than twice per week, any limitation of activities, any nocturnal&#xD;
             symptoms/awaking, need for reliever/rescue inhaler more than twice per week, or known&#xD;
             lung function (PEF or FEV1) without administration of a bronchodilator that is &lt; 80%&#xD;
             predicted or personal best (if known)].&#xD;
&#xD;
          -  Current symptomatic congestive heart failure (New York Heart Association &gt; class II),&#xD;
             unstable cardiac arrhythmia requiring therapy (e.g. medication or pacemaker), unstable&#xD;
             angina (e.g. new, worsening or persistent chest discomfort), or uncontrolled&#xD;
             hypertension (systolic &gt; 160 mmHg or diastolic &gt; 100mmHg). Or any of the following&#xD;
             occurring within 6 months (180 days) prior to first dose of study drugs: Myocardial&#xD;
             infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or&#xD;
             transient ischemic attack. (Use of antihypertensive medication to control blood&#xD;
             pressure is allowed.)&#xD;
&#xD;
          -  Concurrent treatment with a non-permitted drug (refer to prohibited medication list)&#xD;
             as well as foods or supplements that are strong or moderate CYP3A4 enzyme inducers or&#xD;
             inhibitors. Any of the above has to be discontinued at least 7 days prior to Cycle 1/&#xD;
             Day 1 of study treatment.&#xD;
&#xD;
          -  Requirement of anticoagulant therapy with oral vitamin K antagonists such as Coumadin&#xD;
             (warfarin). Low-dose anticoagulants for the maintenance of patency in a central venous&#xD;
             access device or the prevention of deep vein thrombosis or pulmonary embolism is&#xD;
             allowed. Therapeutic use of low molecular weight heparin is allowed provided patients&#xD;
             are safely able to interrupt it prior to biopsy procedures.&#xD;
&#xD;
          -  Persisting toxicity related to prior therapy that has not reduced to Grade 1 [National&#xD;
             Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.0];&#xD;
             however, alopecia and sensory neuropathy Grade ≤ 2 are acceptable and Grade ≤ 2&#xD;
             non-hematological toxicities well controlled with medical management are allowed (for&#xD;
             example: hypomagnesemia well controlled on magnesium replacement).&#xD;
&#xD;
          -  Known severe (Grade ≥ 3 NCI-CTCAE) hypersensitivity reactions to monoclonal&#xD;
             antibodies, or history of anaphylaxis.&#xD;
&#xD;
          -  Vaccination within 28 days of the first dose of study drugs and while on trial is&#xD;
             prohibited, except for administration of inactivated vaccines (for example,&#xD;
             inactivated influenza vaccine).&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  Known current alcohol or drug abuse&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated.&#xD;
&#xD;
          -  Known psychiatric condition, social circumstance, or other medical condition&#xD;
             reasonably judged by the patient's study physician to unacceptably increase the risk&#xD;
             of study participation; or to prohibit the understanding or rendering of informed&#xD;
             consent or anticipated compliance with scheduled visits, treatment schedule,&#xD;
             laboratory tests and other study requirements.&#xD;
&#xD;
          -  Known risk factors for ocular toxicity, consisting of any of the following (Cobi arm&#xD;
             only):&#xD;
&#xD;
               -  presence of serous retinopathy within 6 months of protocol enrollment&#xD;
&#xD;
               -  presence of retinal vein occlusion (RVO) within 6 months of protocol enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>3720932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <results_first_submitted>June 10, 2021</results_first_submitted>
  <results_first_submitted_qc>August 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2021</results_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Ingrid Mayer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03566485/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited to this study from July 2018 to November 2019 at Vanderbilt-Ingram Cancer Center in Nashville, TN. This study stopped early due to low accrual.</recruitment_details>
      <pre_assignment_details>Twelve participants were enrolled onto this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
          <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
        </group>
        <group group_id="P2">
          <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
          <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7">Dose level 1 (Idasanutlin 100mg PO)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
          <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
        </group>
        <group group_id="B2">
          <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
          <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)</title>
        <description>Assessment of DLT for the patients in the atezolizumab and idasanutiln arm of the study</description>
        <time_frame>At 28 days</time_frame>
        <population>patients in the atezolizumab and idasanutiln arm of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
            <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)</title>
          <description>Assessment of DLT for the patients in the atezolizumab and idasanutiln arm of the study</description>
          <population>patients in the atezolizumab and idasanutiln arm of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (Phase I)</title>
        <description>Assessment of MTD for the atezolizumab and idasanutiln combination arm of the study</description>
        <time_frame>At 28 days</time_frame>
        <population>Patients in the atezolizumab and idasanutiln combination arm of the study. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
            <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (Phase I)</title>
          <description>Assessment of MTD for the atezolizumab and idasanutiln combination arm of the study</description>
          <population>Patients in the atezolizumab and idasanutiln combination arm of the study. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not enough patients were put on the Idasa + Atezo arm; therefore, unable to determine MTD. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase II Dose (Phase I)</title>
        <description>Assessment of recommended phase II dose for the atezolizumab and idasanutiln combination arm of the study</description>
        <time_frame>At 28 days</time_frame>
        <population>Patients on the atezolizumab and idasanutiln combination arm of the study. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
            <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase II Dose (Phase I)</title>
          <description>Assessment of recommended phase II dose for the atezolizumab and idasanutiln combination arm of the study</description>
          <population>Patients on the atezolizumab and idasanutiln combination arm of the study. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not enough patients were put on the Idasa + Atezo arm; therefore, unable to determine MTD and recommend dose for phase II. Dosage used: Atezolizumab 840mg IV + Idasanutlin 100mg PO. For phase II, no patients were assigned to this arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)</title>
        <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
        <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)</title>
          <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Among the 5 participants, two patients had only baseline measurements, one patient had only follow up measurement, and one patient did not have any measurements. Only one patient had progressive disease after baseline measurement. Therefore, not enough number of patients for calculating this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR) (Phase II)</title>
        <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses + stability of disease at 6 months seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>At 6 months</time_frame>
        <population>patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR) (Phase II)</title>
          <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of complete and partial responses + stability of disease at 6 months seen in patients with measurable disease. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Among 5 participants, two patients had only baseline measurements, one patient had only follow up measurement, and one patient did not have any measurements. Only one patient had progressive disease after baseline measurement. Therefore, not enough number of patients for calculating this outcome.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Related Response Criteria (irRC) (Phase II)</title>
        <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of immune-related complete and partial responses seen in patients with measurable disease</description>
        <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
        <population>An insufficient number of participants exhibited response for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Related Response Criteria (irRC) (Phase II)</title>
          <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measure the rate (%) of immune-related complete and partial responses seen in patients with measurable disease</description>
          <population>An insufficient number of participants exhibited response for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) (Phase II) in Days</title>
        <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and disease progression.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1).</description>
        <time_frame>At 12 months</time_frame>
        <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) (Phase II) in Days</title>
          <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and disease progression.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1).</description>
          <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="51" upper_limit="NA">Could not be estimated from the data due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) (Phase II) in Days</title>
        <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and death from any cause</description>
        <time_frame>At 12 months</time_frame>
        <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) (Phase II) in Days</title>
          <description>Assessment of clinical impact (anti-tumor effect) of the combination of atezolizumab and cobimetinib or idasanutiln in patients with metastatic ER&#xD;
+ breast cancer by measuring the interval (in months) between treatment initiation and death from any cause</description>
          <population>Patients on Phase 2 Arm 1 (TP53-mut) - Atezolizumab 840mg IV + Cobimetinib 60mg PO</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" lower_limit="136" upper_limit="NA">Could not be estimated from the data due to insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (Phase II)</title>
        <description>Assessment of adverse events throughout the phase II study</description>
        <time_frame>Up to 28 days after completion of study treatment, for a total of 2 years</time_frame>
        <population>patients on atezolizumab and cobimetinib.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
            <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (Phase II)</title>
          <description>Assessment of adverse events throughout the phase II study</description>
          <population>patients on atezolizumab and cobimetinib.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initiation of study medication, throughout the study, and within 28 days (+/- 7 days) of the last dose of study medication, for a total of 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 2 (Atezolizumab, Cobimetinib)</title>
          <description>Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Atezolizumab: Given by IV&#xD;
Cobimetinib: Given by mouth</description>
        </group>
        <group group_id="E2">
          <title>Phase 1b - (Atezolizumab, Idasanutlin)</title>
          <description>Atezolizumab: Given by IV&#xD;
Idasanutlin: Given by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Strep infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Clinical progression</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v5.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vison</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Teresa Melton</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>6159367423</phone>
      <email>teresa.melton@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

